Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Samantha Prout Biography and Net Worth

Insider of Amicus Therapeutics

Samantha Whiteman Prout CPA serves as Principal Accounting Officer, Vice President - Finance, Controller of the Company. Prior to joining Amicus, Ms. Prout spent nearly three years at NRG Energy (“NRG”), first as Controller for Home Solar division, then as the Director of Financial Reporting. Prior to joining NRG, Ms. Prout spent over 15 years at KPMG LLP, the final nine as an Audit Senior Manager serving the life science practice in New Jersey. Ms. Prout received a Bachelor of Arts from Gettysburg College and is a certified public accountant in New Jersey.

What is Samantha Prout's net worth?: The estimated net worth of Samantha Prout is at least $873,096.90 as of January 8th, 2024. Ms. Prout owns 82,290 shares of Amicus Therapeutics stock worth more than $873,097 as of April 19th. This net worth estimate does not reflect any other investments that Ms. Prout may own. Learn More about Samantha Prout's net worth.
How old is Samantha Prout?: Ms. Prout is currently 46 years old. There are 5 older executives and no younger executives at Amicus Therapeutics. The oldest executive at Amicus Therapeutics is Mr. Simon Nicolas Reade Harford, Chief Financial Officer, who is 64 years old. Learn More on Samantha Prout's age.
How do I contact Samantha Prout?: The corporate mailing address for Ms. Prout and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Samantha Prout's contact information.
Has Samantha Prout been buying or selling shares of Amicus Therapeutics?: Samantha Prout has not been actively trading shares of Amicus Therapeutics within the last three months. Most recently, Samantha Prout sold 30,767 shares of the business's stock in a transaction on Monday, January 8th. The shares were sold at an average price of $14.00, for a transaction totalling $430,738.00. Following the completion of the sale, the chief accounting officer now directly owns 82,290 shares of the company's stock, valued at $1,152,060. Learn More on Samantha Prout's trading history.
Who are Amicus Therapeutics' active insiders?: Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 42 times. They sold a total of 526,511 shares worth more than $6,805,375.39. The most recent insider tranaction occured on March, 5th when Director Margaret G Mcglynn sold 7,500 shares worth more than $100,500.00. Insiders at Amicus Therapeutics own 2.1% of the company. Learn More about insider trades at Amicus Therapeutics.
Information on this page was last updated on 3/5/2024.

Samantha Prout Insider Trading History at Amicus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/8/2024	Sell	30,767	$14.00	$430,738.00	82,290
12/26/2023	Sell	7,659	$14.00	$107,226.00	121,912
8/9/2023	Sell	36,909	$14.01	$517,095.09	137,003
9/3/2021	Sell	4,925	$12.01	$59,149.25	85,150
8/23/2021	Sell	5,045	$11.00	$55,495.00	83,170
11/4/2020	Sell	5,931	$20.00	$118,620.00	22,472
8/5/2020	Sell	198	$15.05	$2,979.90	17,333
7/2/2020	Sell	198	$15.80	$3,128.40	1,733
6/19/2020	Sell	3,366	$15.00	$50,490.00	20,501

Samantha Prout Buying and Selling Activity at Amicus Therapeutics

Amicus Therapeutics Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $10.61

$10.24

$10.66

50 Day Range

MA: $12.18

$10.33

$14.00

2 Week Range

Now: $10.61

$9.70

$14.57

Volume

2,501,714 shs

Average Volume

3,002,690 shs

Market Capitalization

$3.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad